Drug Interactions Between Wegovy (Semaglutide), Lithium, and Levothyroxine

It is safe to start Wegovy (semaglutide) in an adult patient on lithium and levothyroxine, but this combination requires vigilant monitoring of lithium levels, thyroid function, and hydration status due to documented pharmacokinetic interactions.

Critical Drug Interactions and Monitoring Requirements

Semaglutide-Lithium Interaction: High-Risk Combination

The most concerning interaction is between semaglutide and lithium, which can precipitate lithium toxicity even when lithium doses and renal function remain stable. 1

Recent case series document significant increases in lithium levels after semaglutide initiation, with two patients developing frank lithium toxicity despite unchanged lithium dosing and stable kidney function 1
In a third documented case, preemptive lithium dose reduction mitigated toxicity, though lithium levels still rose higher than expected 1

Mechanisms Underlying Lithium Toxicity Risk

The interaction likely occurs through multiple pathways 1:

Dehydration from reduced oral intake – semaglutide's appetite-suppression effect decreases fluid consumption
GI fluid losses – nausea (40–44% incidence), vomiting, and diarrhea cause volume depletion 2, 1
Delayed gastric emptying – may alter lithium absorption kinetics 1
Potential renal effects – though not fully elucidated, GLP-1 receptor agonists may subtly influence lithium clearance 1

Mandatory Lithium Monitoring Protocol

Before initiating semaglutide 1:

Obtain baseline serum lithium level
Measure serum creatinine and calculate eGFR
Assess hydration status clinically

During semaglutide titration 1:

Check lithium levels weekly for the first month, then every 2 weeks through month 3
Monitor for lithium toxicity symptoms: tremor, confusion, ataxia, polyuria, nausea
Measure serum creatinine monthly during dose escalation

Consider preemptive lithium dose reduction of 10–20% when starting semaglutide, particularly if baseline lithium level is in the upper therapeutic range (>0.8 mEq/L) 1

Semaglutide-Levothyroxine Interaction: Moderate Clinical Significance

Oral semaglutide increases levothyroxine absorption by approximately 33%, though this interaction is less pronounced with injectable semaglutide (Wegovy). 3

A pharmacokinetic study demonstrated a 33% increase in total thyroxine (T4) exposure when levothyroxine was co-administered with oral semaglutide 14 mg at steady state 3
The maximum concentration (Cmax) of T4 was unaffected, suggesting delayed rather than enhanced absorption 3
The interaction is attributed to semaglutide's delayed gastric emptying, which prolongs levothyroxine contact time with the intestinal mucosa 3

Thyroid Monitoring Strategy

Baseline assessment 2, 3:

Measure TSH and free T4 before starting semaglutide
Document current levothyroxine dose and timing

During semaglutide therapy 3:

Recheck TSH and free T4 at 6–8 weeks after reaching semaglutide maintenance dose (2.4 mg weekly)
Monitor for hyperthyroid symptoms: palpitations, tremor, weight loss, anxiety
If TSH becomes suppressed (<0.4 mIU/L), reduce levothyroxine dose by 12.5–25 mcg

Dosing separation strategy 3:

Continue taking levothyroxine on an empty stomach, 30–60 minutes before breakfast
Administer Wegovy injection at a different time of day (e.g., evening) to minimize temporal overlap

Lithium-Levothyroxine Interaction: Pre-Existing Consideration

Lithium independently increases the risk of hypothyroidism, making thyroid monitoring essential even before semaglutide is introduced. 4, 5

Lithium causes goiter in up to 40% of patients and clinical hypothyroidism in approximately 20% 4
Lithium increases thyroid autoimmunity (anti-TPO and anti-TG antibodies) if autoimmune predisposition exists 4, 5
Female patients are more susceptible to lithium-induced thyroid dysfunction 5

This patient is already on levothyroxine, indicating pre-existing hypothyroidism (likely lithium-induced). The addition of semaglutide creates a three-way interaction requiring integrated monitoring 4, 5, 3.

Comprehensive Monitoring Algorithm

Pre-Initiation Workup (Before Starting Wegovy)

Laboratory tests 2, 1, 3:

Serum lithium level (therapeutic range 0.6–1.2 mEq/L)
Serum creatinine and eGFR
TSH and free T4
Electrolytes (sodium, potassium)
Pregnancy test (βHCG) if applicable 2

Clinical assessment 1:

Hydration status (skin turgor, mucous membranes, orthostatic vital signs)
Current lithium toxicity symptoms (tremor, confusion, ataxia)
Thyroid symptom review (fatigue, cold intolerance, palpitations)

Medication reconciliation 2:

Document exact lithium formulation and dosing schedule
Confirm levothyroxine dose and administration timing
Identify other medications that affect lithium clearance (NSAIDs, ACE inhibitors, thiazide diuretics)

Semaglutide Titration Schedule with Integrated Monitoring

Weeks 1–4: Semaglutide 0.25 mg weekly 2:

Check lithium level at week 2 and week 4 1
Monitor for GI side effects (nausea, vomiting, diarrhea) 2
Counsel patient on maintaining fluid intake (≥2 liters/day) 1

Weeks 5–8: Semaglutide 0.5 mg weekly 2:

Check lithium level at week 6 and week 8 1
Assess hydration status at each visit 1
Monitor weight and blood pressure 2

Weeks 9–12: Semaglutide 1.0 mg weekly 2:

Check lithium level at week 10 and week 12 1
Measure serum creatinine 1

Weeks 13–16: Semaglutide 1.7 mg weekly 2:

Check lithium level at week 14 and week 16 1

Week 17+: Semaglutide 2.4 mg weekly (maintenance) 2:

Check lithium level at week 18, week 20, and week 24 1
Measure TSH and free T4 at week 24 (6–8 weeks after reaching maintenance dose) 3

Long-Term Monitoring (After Reaching Maintenance Dose)

Lithium monitoring 1:

Every 3 months for the first year
Every 6 months thereafter if levels remain stable
More frequently if dose adjustments are made

Thyroid monitoring 3, 4:

TSH and free T4 every 6 months
Sooner if symptoms of hypo- or hyperthyroidism develop

Renal function 1:

Serum creatinine and eGFR every 6 months
More frequently if lithium levels become elevated

Timing and Administration Adjustments

Levothyroxine Dosing Strategy

Maintain standard levothyroxine administration 3:

Take on empty stomach, 30–60 minutes before breakfast
Avoid co-administration with calcium, iron, or proton pump inhibitors

Wegovy injection timing 3:

Administer at a different time of day than levothyroxine (e.g., evening)
This temporal separation minimizes the gastric-emptying effect on levothyroxine absorption

Lithium Dosing Considerations

Consider preemptive dose reduction 1:

If baseline lithium level is 0.8–1.2 mEq/L, reduce lithium dose by 10–20% when starting semaglutide
If baseline lithium level is 0.6–0.8 mEq/L, maintain current dose but monitor closely

Hydration counseling 1:

Instruct patient to drink ≥2 liters of water daily
Increase fluid intake during hot weather or exercise
Avoid excessive caffeine (diuretic effect)

Red Flags and When to Hold or Discontinue Semaglutide

Lithium Toxicity Warning Signs 1

Immediately check lithium level and hold semaglutide if 1:

Coarse tremor (worse than baseline fine tremor)
Confusion, disorientation, or altered mental status
Ataxia or gait instability
Polyuria (>3 liters/day) or polydipsia
Severe nausea, vomiting, or diarrhea lasting >24 hours

Discontinue semaglutide if 1:

Lithium level exceeds 1.5 mEq/L
Signs of severe lithium toxicity (seizures, coma, renal failure)

Thyroid-Related Concerns 3

Hold semaglutide and recheck thyroid function if 3:

TSH becomes suppressed (<0.1 mIU/L) with symptoms of hyperthyroidism
New-onset palpitations, tremor, or anxiety

Absolute Contraindications to Semaglutide 2

Do not initiate Wegovy if 2:

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple endocrine neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of severe hypersensitivity to semaglutide

Patient Education Priorities

Hydration and Lithium Safety 1

"Drink at least 8 glasses of water daily, even if you're not thirsty" – semaglutide reduces appetite and thirst
"Call immediately if you develop severe vomiting or diarrhea" – these increase lithium toxicity risk
"Watch for new tremor, confusion, or unsteady walking" – early signs of lithium toxicity

Thyroid Symptom Awareness 3

"Report new palpitations, anxiety, or unexplained weight loss" – may indicate excessive thyroid hormone
"Continue taking levothyroxine as prescribed" – do not adjust dose without provider guidance

Expected GI Side Effects 2

"Nausea is common (40% of patients) but usually improves after 4–8 weeks" 2
"Eat smaller, more frequent meals" – helps manage nausea
"Avoid high-fat, greasy foods" – worsens GI symptoms

Common Pitfalls to Avoid

Do not assume stable lithium levels mean no monitoring is needed – the semaglutide-lithium interaction can emerge at any point during therapy 1

Do not attribute all GI symptoms to semaglutide – severe, persistent nausea or vomiting may indicate lithium toxicity 1

Do not delay thyroid function testing – check TSH/free T4 at 6–8 weeks after reaching semaglutide maintenance dose, not sooner or later 3

Do not discontinue levothyroxine if TSH becomes suppressed – reduce the dose by 12.5–25 mcg and recheck in 6 weeks 3

Do not ignore dehydration risk – patients on lithium are particularly vulnerable to volume depletion from semaglutide's GI effects 1

Summary: Safe Initiation Protocol

Obtain baseline labs: lithium level, creatinine, TSH, free T4 2, 1, 3
Consider preemptive lithium dose reduction (10–20%) if level is >0.8 mEq/L 1
Start semaglutide at 0.25 mg weekly with slow titration over 16 weeks 2
Monitor lithium levels weekly for the first month, then every 2 weeks through month 3 1
Check TSH/free T4 at 6–8 weeks after reaching 2.4 mg maintenance dose 3
Counsel on hydration (≥2 liters/day) and lithium toxicity warning signs 1
Separate levothyroxine and Wegovy administration by time of day 3

This combination is manageable with appropriate monitoring, but requires closer surveillance than semaglutide monotherapy. 1, 3

Is it safe for an adult patient on lithium for bipolar disorder and levothyroxine for hypothyroidism to start Wegovy (semaglutide) for weight loss, and what monitoring and timing adjustments are required?

Help us tailor your experience